Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768972 | PMC |
| http://dx.doi.org/10.1093/neuonc/noad166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SPECTRO GLIO trial aftermath: Where do we go from here?
Neuro Oncol
January 2024
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).
Neuro Oncol
January 2024
Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, RadOpt-CRCT-INSERM, Toulouse, France.
Background: Glioblastoma (GBM) systematically recurs after a standard 60 Gy radio-chemotherapy regimen. Since magnetic resonance spectroscopic imaging (MRSI) has been shown to predict the site of relapse, we analyzed the effect of MRSI-guided dose escalation on overall survival (OS) of patients with newly diagnosed GBM.
Methods: In this multicentric prospective phase III trial, patients who had undergone biopsy or surgery for a GBM were randomly assigned to a standard dose (SD) of 60 Gy or a high dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, the tumor bed and residual contrast enhancements.
Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?
Radiother Oncol
June 2023
Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, Radiation Oncology, Toulouse, France; ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France.
Article Synopsis
- The study focuses on glioblastoma, an aggressive brain tumor, and aims to differentiate its metabolic components to improve treatment and survival rates using proton MR spectroscopic imaging (MRSI).
- Researchers analyzed MRSI data from 180 patients, applying clustering techniques to identify five metabolic clusters, with some showing abnormalities linked to progression-free survival (PFS).
- Results indicate that specific clusters, particularly those with high lactate levels, can predict poorer outcomes, highlighting the importance of tumor metabolic profiling in treatment planning.
[Radiation dose intensification for glioblastoma].
Cancer Radiother
October 2022
Département d'oncologie radiothérapie, institut universitaire du cancer de Toulouse-Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex, France; Inserm Radopt, CRCT, Centre de recherche en cancérologie de Toulouse, 2, avenue Hubert-Curien, 31100 Toulouse, France.
Glioblastoma is the most common brain tumor in adults; its treatment includes surgical excision or biopsy followed by radio-chemotherapy. Even if radiotherapy increases the survival of all patients regardless of their age or their general condition, there are always sources of radioresistance, where relapses occur and therefore treatment fails. Indeed, these foci result in a local relapse, which is observed in 95% of cases in the irradiation fields.
View Article and Find Full Text PDFDose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
BMC Cancer
February 2019
Radiation Oncology Department, Institut Claudius Regaud- Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Background: Glioblastoma, a high-grade glial infiltrating tumor, is the most frequent malignant brain tumor in adults and carries a dismal prognosis. External beam radiotherapy (EBRT) increases overall survival but this is still low due to local relapses, mostly occurring in the irradiation field. As the ratio of spectra of choline/N acetyl aspartate> 2 (CNR2) on MR spectroscopic imaging has been described as predictive for the site of local relapse, we hypothesized that dose escalation on these regions would increase local control and hence global survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!